

Susan Hess Ph.D.  
Senior Patent Attorney

973 781 8060 P.01

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building  
430  
East Hanover NJ 07936-  
1080

Tel (973) 781-8060  
Fax (973) 781-8064  
Internet: susan.hess  
@group.novartis.com



Fax

**RECEIVED**  
**CENTRAL FAX CENTER**

DEC 10 2003

**OFFICIAL**

Attention      United States Patent and Trademark Office  
 Fax no.      703-872-9306  
 Number of pages      including cover page -- 23  
 Date      December 4, 2003  
 Concerning      U.S. Patent Application for  
 AMLOT ET AL.  
 Application No. 09/770,002  
 Our Case No. 4-30583A/30967/C1

Sir:

Please see attached.

Very truly yours,

Susan Hess

SH:pmm

**CONFIDENTIALITY NOTICE**


THIS FAX CONTAINS CONFIDENTIAL INFORMATION WHICH MAY BE PRIVILEGED AND IS INTENDED SOLELY FOR THE USE OF THE ABOVE-NAMED RECIPIENT(S). IT MAY BE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT AN INTENDED RECIPIENT OR PERSON RESPONSIBLE FOR DELIVERY OF THIS FAX TO AN INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS FAX IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISCLOSURE, COPYING OR OTHER USE OF THIS FAX OR ITS CONTENTS IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE AT ONE OF THE NUMBERS LISTED ON THE RECIPIENT(S) LINE.

CASE 4-30583A

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Susan Hess  
Type or print name

  
Signature

December 4, 2003  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****IN RE APPLICATION OF****Art Unit: 1644****AMLOT ET AL.****Examiner: Gerald Ewoldt****APPLICATION NO: 09/770,002****FILED: JANUARY 25, 2001****FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF  
RHEUMATOID ARTHRITIS OR SKIN DISEASES**


**MS: After Final**  
 Commissioner for Patents  
 PO Box 1450  
 Alexandria, VA 22313-1450

**COMMUNICATION**

Sir:

In a telephone call on December 2, 2003, the Examiner in charge of the above-identified case indicated that he did not receive a response to the Final Action mailed on April 28, 2003. Applicants informed the Examiner that a response was timely filed on October 28, 2003 along with a petition for a three month extension of time. The Examiner requested that we resubmit the response by facsimile. Attached hereto is the previously submitted response and the petition for extension of time, along with a copy of the date-stamped postcard returned from the PTO indicating that the response was timely filed on October 28, 2003. Applicants respectfully request that the presently filed papers upon their receipt be matched with the file and forwarded to the Examiner.

Respectfully submitted,

  
 Susan Hess  
 Attorney for Applicants  
 Reg. No. 37,350

Novartis  
 Corporate Intellectual Property  
 One Health Plaza, Building 430  
 East Hanover, NJ 07936-1080  
 (862) 778-7859

Dat : December 4, 2003

Response Under 37 CFR §1.116  
Expedited Procedure  
Examining Group 1632

CASE 4-30583A

**FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10**

EV335543080US  
Express Mail Label Number

OCTOBER 28, 2003  
Date of Deposit

**RECEIVED**  
**CENTRAL FAX CENTER**

DEC 10 2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1644

AMLOT ET AL.

Examiner: Gerald Ewoldt

APPLICATION NO: 09/770,002

FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF  
RHEUMATOID ARTHRITIS OR SKIN DISEASES**OFFICIAL**

**MS: After Final**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**RESPONSE AFTER FINAL REJECTION**

Sir:

This is in response to the Office Action dated April 28, 2003 having a shortened three month period for response which expired on July 28, 2003. Applicants enclose herewith a petition for a three month extension of time together with authorization to deduct the appropriate fee.

Remarks begin on page 2 of this paper.